Cannabis Stock News- Investing in Cannabis and Hemp Stocks

Tuesday, December 22, 2020

Investor Ideas #Potcasts 510, #Cannabis News and #Stocks on the Move (TSX: $WEED.TO) (NASDAQ: $CGC) (TSX: $RIV.TO) (CSE: $HOLL.C) (TSX: $VFF.TO)

Investor Ideas #Potcasts 510, #Cannabis News and #Stocks on the Move (TSX: $WEED.TO) (NASDAQ: $CGC) (TSX: $RIV.TO) (CSE: $HOLL.C) (TSX: $VFF.TO)

Delta, Kelowna, BC, December 22, 2020 (Investorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, www.potcasts.ca release today’s podcast edition of cannabis news and stocks to watch plus insight from thought leaders and experts.

Listen to the podcast:

https://www.investorideas.com/Audio/Podcasts/2020/122220-StocksToWatch.mp3

Read this in full at https://www.investorideas.com/news/2020/cannabis-potcasts/12221WEED-CGC-RIV-HOLL-VFF.asp

Hear the investor ideas potcast on Spotify

Hear Investor ideas cannabis potcast on iTunes

Today’s podcast overview/transcript:

Good afternoon and welcome to another episode of Investorideas.com "Potcast" featuring cannabis news, stocks to watch as well as insights from thought leaders and experts.

In today’s podcast we will be looking at a few private and public company announcements.

Canopy Growth Corporation (TSX: WEED) (NASDAQ: CGC) announced that it has entered into an arrangement agreement with its wholly-owned subsidiary The Tweed Tree Lot Inc., Canopy Rivers Inc. (TSX: RIV) and its wholly-owned subsidiary Canopy Rivers Corporation pursuant to which Canopy Growth will acquire certain assets from CRC, as set out below, in exchange for cash, common shares in the capital of Canopy Growth and the surrender of all shares in the capital of Canopy Rivers held by Canopy Growth by way of a plan of arrangement under the Business Corporations Act (Ontario).

"Canopy Rivers was established in 2017 as a strategic investment vehicle for Canopy Growth, helping us pursue key business opportunities including development of the Vert Mirabel greenhouse which today is a very important component of our Canadian cannabis operations," said David Klein, CEO, Canopy Growth. "With our new strategy in place, it is appropriate for us to divest our interest in Canopy Rivers to increase our focus as a company."

Pursuant to the Arrangement, Canopy Growth will increase its fully-diluted conditional ownership in TerrAscend Corp. ("TerrAscend") from approximately 13% to approximately 21% through the acquisition of (i) 19,445,285 exchangeable shares in the capital of TerrAscend; (ii) 2,225,714 common share purchase warrants in the capital of TerrAscend with an exercise price of $5.95 per share; (iii) 333,723 common share purchase warrants in the capital of TerrAscend with an exercise price of $6.49 per share; and (iv) a $13.2 million loan receivable owing by TerrAscend Canada Inc. to CRC. The securities in the capital of TerrAscend are not currently convertible or exercisable, and will not be convertible or exercisable until federal laws in the United States with respect to marijuana are amended.

Subject to certain rights of first refusal, Canopy Growth will also acquire all of the common shares and Class A preferred shares in the capital of Les Serres Vert Cannabis Inc. ("Vert Mirabel") held by CRC, thereby increasing Canopy Growth's ownership of the issued and outstanding common shares in the capital of Vert Mirabel from approximately 41% to approximately 67%.

In addition, all of the obligations of Tweed NB, a Fredericton, New Brunswick based subsidiary of Canopy Growth that was recently closed, owing to CRC pursuant to a royalty agreement between the parties will be terminated. The termination of the royalty agreement will provide Canopy Growth with annual cash savings of approximately $2.9 million per year over the balance of the 24-year term of the agreement.

Canopy Growth currently owns 36,468,318 Class B multiple voting shares ("MVS") and 15,223,938 Class A subordinate voting shares ("SVS") in the capital of Canopy Rivers, which represent approximately a 27% ownership interest and 84% of the aggregate voting rights of Canopy Rivers. Pursuant to the Arrangement, all of the MVS and SVS held by Canopy Growth will be repurchased by Canopy Rivers for cancellation on a cashless basis. Canopy Growth will not have any equity, debt or other interest in Canopy Rivers following completion of the Arrangement.

As additional consideration for the assets being transferred and the termination of the royalty agreement, Canopy Growth will make a cash payment to CRC of $115 million and issue an aggregate of 3,750,000 Canopy Growth Shares.

Hollister Biosciences Inc. (CSE: HOLL) (OTC: HSTRF) a diversified cannabis branding company with products in over 280 dispensaries throughout California, and over 80 dispensaries throughout Arizona, announced the launch of its 2nd fulfillment depot for its direct-to-consumer cannabis delivery platform, Dreamy Delivery.

The Company soft launched Dreamy Delivery to friends and family in the San Francisco Bay Area of Northern California, to ensure a seamless customer experience in early Q4 of 2020. The Company has expanded the Platform, with Dreamy now successfully delivering to legal cannabis consumers in the San Francisco Bay Area of Northern California and now Sacramento, California. The Company hopes to launch Dreamy in the Central Coast of California by early Q1 of 2021 with the ultimate goal of delivering Cannabis statewide.

Carl Saling, CEO of Hollister, shared, "Very excited to have opened our 2nd direct to consumer delivery depot in record time, allowing us to serve legal adults in the Sacramento Area. This furthers our quest to be a dominate direct to consumer delivery platform in California."

Pure Sunfarms, the wholly owned subsidiary of Village Farms International (TSX: VFF) (NASDAQ: VFF) announced that their quality, B.C.-grown dried flower products are now available to Canadian patients through a supply agreement with Medical Cannabis by Shoppers Inc., a subsidiary of Shoppers Drug Mart Inc., one of Canada’s leading health, beauty and convenience retailers. Medical consumers in provinces and territories across Canada will now have access to Pure Sunfarms’ cannabis products, including 14g and 28g packs of dried flower.

The first of Pure Sunfarms’ cannabis products available include five varieties of 28g packs, and assorted sizes of signature strains Afghan Kush, White Rhino, Island Honey, Pink Kush, D. Bubba, and Headband. Pre-roll, oil and vape offerings will become available to Medical Cannabis by Shoppers patients in early 2021.

Registered patients across Canada can now purchase Pure Sunfarms’ products through the Medical Cannabis by Shoppers marketplace, the largest national platform providing medical consumers with convenient, one-stop access to a broad assortment of safe, high-quality products to meet their medical cannabis needs. A dedicated team of cannabis-trained advisors and Pharmacists are available by phone or email for those patients who require guidance and support.

“This agreement is a big milestone for Pure Sunfarms as the leading producer of B.C.-grown cannabis products in Canada. This marks the first time medical patients in all provinces and territories will have access to the widest selection of our dried flower products,” said Mandesh Dosanjh, President & CEO, Pure Sunfarms. “We’re thrilled to partner with the Medical Cannabis by Shoppers team, to offer consumers more choice and access to our products as the medical space evolves and grows in Canada.”

MagicMed Industries Inc. announced today that it has completed the establishment of the psilocybin-derivatives patent portfolio of the PsybraryTM and the launch of the Candidate Selection program. The PsybraryTM is a proprietary physical and knowledgebase collection of novel psychedelic-derivative drug candidates, manufacturing methods, pharmacological data, and patent filings that protect all of the above.

MagicMed's Chief Scientific Officer, Dr. Peter Facchini, stated "Our psilocybin-derivatives portfolio, which also captures dimethyltryptamine (DMT) derivatives, now includes 12 filed patent applications directed to 9 different chemical compound categories covering over 125 million individual molecules. While we certainly don't expect to synthesize all of these molecules during the development of new drug candidates, I am pleased to announce that, as of today's launch of the Candidate Selection program, we have already synthesized more than 100 distinct psilocybin-derivative drug candidates in our state-of-the-art research and development facilities".

MagicMed's Intellectual Property Advisor, Dr. Harm Deckers, continued, "Filing this broad portfolio of patent applications is an important moment for the Company. Now that these patent applications claiming composition, manufacture, and methods of use are on file with the U.S. Patent and Trademark Office, international patent treaties prevent worldwide the issuance of claims to other parties, should any file patent applications in the future on any of these 125 million molecules".

Mental illness is a ubiquitous human experience and an insufficiently addressed medical need. Psychedelic-associated therapies offer an alternative to ineffective treatments, yet the psychedelic-based drugs themselves require improvement to achieve reduced side effects, better efficacy, and broader patient access. The mission of MagicMed is to develop the PsybraryTM to deliver such much needed improved drug candidates to its biotechnology and pharmaceutical partners.

Investor ideas reminds all listeners to read our disclaimers and disclosures on the Investorideas.com website and that this podcast is not an endorsement to buy products or services or securities. Investors are reminded all investment involves risk and possible loss of investment.

Investors can trade these stocks and other ideas on our site using our list of top stock trading apps including Robinhood, Acorn, Stash and others.

Learn more about our cannabis podcasts at https://www.investorideas.com/Audio/Potcasts.asp

Or www.potcasts.ca

Hear Investor ideas cannabis potcast on iTunes

Hear the investor ideas potcast on Spotify

To hear more Investorideas.com podcasts visit: https://www.investorideas.com/Audio/.

Investorideas.com podcasts are also available on iTunes, Spotify, Google Play Music, Stitcher, Spreaker, YouTube via Spreaker, iHeartradio and Tunein.

Potcasts is now a certified word mark Trademark on the blockchain through Cognate, Inc. CM Certification-Registration Number: 10468217708

About Investorideas.com - News that Inspires Big Investing Ideas

Investorideas.com is a recognized news source publishing third party news, research and original financial content. Learn about investing in stocks and sector trends with our news alerts, articles, podcasts and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy and more. Investor Idea’s original branded content includes the following podcasts and columns : Crypto Corner , Play by Play sports and stock news column, Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast and column, Cleantech and Climate Change , Exploring Mining the AI Eye .

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy:

https://www.investorideas.com/About/Private_Policy.asp

Investor Ideas does not condone the use of cannabis except where permissible by law. Our site does not possess, distribute, or sell cannabis products.

Learn more about sponsoring this podcast or be a guest and our other branded content opportunities at Investorideas.com

Download our Mobile App for iPhone and Android

Join our Investor Club https://www.investorideas.com/membership/

Contact Investorideas.com

800 665 0411

Get more Cannabis Stock Investor Ideas – news, articles, podcasts and stock directory

Thursday, December 17, 2020

Investorideas.com - Cannabis Stock News: Emerald Health Therapeutics (TSXV: EMH) (OTCQX: EMHTF) Introduces High Potency SYNC(TM) 100 CBD Oil

Investor Ideas #Potcasts #Podcast #509, #Cannabis News and #Stocks on the Move; (NASDAQ: $VFF) (TSXV: $NUMI.V) (NASDAQ: $APHA) (OTCQB: $PHCG) (NYSE: $XXII)

Investor Ideas #Potcasts #Podcast #509, #Cannabis News and #Stocks on the Move; (NASDAQ: $VFF) (TSXV: $NUMI.V) (NASDAQ: $APHA) (OTCQB: $PHCG) (NYSE: $XXII)

Delta, Kelowna, BC, December 17, 2020 (Investorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, www.potcasts.ca release today’s podcast edition of cannabis news and stocks to watch plus insight from thought leaders and experts.

Listen to the podcast:

https://www.investorideas.com/Audio/Podcasts/2020/121720-StocksToWatch.mp3

Read this in full at https://www.investorideas.com/news/2020/cannabis-potcasts/12171VFF-NUMI-APHA-PHCG-XXII.asp

Hear the investor ideas potcast on Spotify

Hear Investor ideas cannabis potcast on iTunes

Today’s podcast overview/transcript:

Good afternoon and welcome to another episode of Investorideas.com "Potcast" featuring cannabis news, stocks to watch as well as insights from thought leaders and experts.

In today’s podcast we will be looking at a few private and public company announcements.

Village Farms International, Inc. (NASDAQ:VFF) (TSX:VFF) today announced further expansion of its Cannabis 2.0 offerings, including its first cannabis-infused gummy products based on the propriety technology of White Rabbit OG.

Exclusive Partnership with White Rabbit OG for Edibles Formulation and Manufacture

Pure Sunfarms has entered into an exclusive partnership agreement with White Rabbit, a BC-based craft cannabis food formulation and development company, for the formulation and manufacture of edible cannabis-infused gummies using White Rabbit's proprietary EAT ME Technology. EAT ME Technology is a proprietary, all-natural emulsion blend that ensures cannabis extract is dispersed equally in each gummy and increases the bioavailability of the THC and CBD molecules, allowing for consistent results and near-perfect dosing. Edibles from both companies will be distributed and sold by Pure Sunfarms under their respective brands.

Pure Sunfarms and White Rabbit cannabis-infused gummies are expected to be the only gummies in Canada that are made using real pure fruit. In addition, they are plant-based, allergen-free, non-GMO, vegan and preservative-free.

"We are thrilled to exclusively partner with White Rabbit OG to develop a unique product made with real fruit. Pure Sunfarms and White Rabbit both share the fundamental belief in providing consumers with a pure cannabis experience, which we know consumers appreciate," said Mandesh Dosanjh, President and Chief Executive Officer, Pure Sunfarms.

"White Rabbit is a true Canadian leader in the formulation of edibles. Combined with the absorption benefits of White Rabbit's EAT ME Technology, we see lots of potential in this rapidly growing segment of the cannabis market."

"As an innovative craft BC brand, aligning ourselves with a partner who shares our vision and values, sees the opportunities for growth and is intuitive about what cannabis consumers are looking for is important to us," said Kyrsten Dewinetz, Co-Founder and Chief Executive Officer, White Rabbit. "We are excited to have partnered with Pure Sunfarms, a well-respected, fast-growing licensed producer, whose approach and commitment to quality is complementary to our own. Together, we look forward to setting the new standard of cannabis edibles, and delivering products that not only taste great, but provide consumers with a high-quality experience."

"This partnership is yet another example of our' prudent, capital-efficient approach to pursuing growth opportunities in cannabis," said Michael DeGiglio, CEO, Village Farms International. "We expect edibles to be an increasingly meaningful part of the Canadian cannabis market and exclusively partnering with a formulation and technology leader allows for the expedited launch of unique products with minimal capital investment."

Pure Sunfarms plans to launch its Pure Sunfarms-branded cannabis-infused gummies in early 2021, while White Rabbit plans to launch its brand to the recreational cannabis retail markets in British Columbia, Alberta, Saskatchewan, and Ontario, as well as nationally through Medical Cannabis by Shoppers in the coming weeks. White Rabbit's first products will consist of Craft Blueberry and Craft Sour Peach flavours, each offered in packs of four 2.5-mg THC per gummy (total of 10-mg THC per pack), with new flavours and potencies to be added in 2021.

The Pure Sunfarms/White Rabbit partnership agreement is initially for a period of two years, with the option to renew the agreement annually thereafter.

Pure Sunfarms Expands Cannabis 2.0 Offering with Launch of High-THC Vapes and Adds New Strains to its Full Spectrum Vape Collection

Building on the success of its full spectrum vape products, which were launched in Ontario, British Columbia and Alberta, Pure Sunfarms will expand its vape product offering with the introduction of new high-THC vape products in the coming weeks. Each 510 cartridge will feature 840-mg to 900-mg of concentrated THC, intended for consumers seeking a high-THC experience.

"Our high-THC vape products have just one ingredient: pure cannabis extract," said Mr. Dosanjh. "They contain no additives, no alternative botanical ingredients, no flavouring agents, no thinning agents, no additional cannabinoids. And like all Pure Sunfarms' products, they offer consumers quality at an attractive price."

Pure Sunfarms will also add two new strains, Critical Kali Mist and Headband, to their full spectrum vape portfolio in the weeks ahead.

Numinus Wellness Inc. (TSXV: NUMI), a company creating an ecosystem of solutions centred on the research, development, and delivery of safe, evidence-based, accessible psychedelic-assisted psychotherapies, has completed the first legal extraction of Psilocybe mushrooms in Canada by a public company for research and development purposes. This follows Numinus' successful completion of the cultivation and harvest of the first legal flush of Psilocybe mushrooms at Numinus Bioscience, the Company's 7,000 square foot analytics and research laboratory.

"Completing the first legal extraction of Psilocybe mushrooms in Canada is a critical next step to providing a natural product for safe, evidence-based psilocybin-assisted psychotherapies to those in need," said Payton Nyquvest, CEO, Founder, and Chairman. "Numinus continues to be a vanguard of positive change for the industry, and this announcement demonstrates our ability to deliver yet another first."

Numinus Bioscience is establishing itself at the forefront of analytical testing for psychedelic substances, as a centre of excellence for psychedelic product research and development, and as an ancillary for psychedelic therapy clinical trials. Health Canada licences, scientific expertise, and state-of-the-art technologies facilitate ongoing innovation, while revenue from high-throughput contract cannabis testing is reinvested to further its psychedelic initiatives.

"This is an important milestone in our comprehensive research strategy, following our successful harvest announced in October," said Sharan Sidhu, Science Officer and General Manager. "In the extraction process, Numinus Bioscience's goal is to optimize Psilocybe mushrooms to standardize psilocybin and multiple therapeutically important components, increasing the efficacy of the extract. To further our position as a centre of excellence in the space, we are in the process of submitting amendments to supply the extract for use in clinical trials and the Special Access Programme, which, when accepted, will mark a significant move forward in scaling the delivery of psychedelic-assisted therapies."

"While direct comparisons cannot be made, there is a clear recognition in the cannabis space that synthetic cannabinoids are far less attractive than naturally occurring cannabinoids," indicated Dr. Evan Wood, Numinus' Chief Medical Officer. "Numinus is of the view that, ultimately, nature knows best, and we're excited to be at the forefront of exploring the fascinating world of working with Psilocybe mushrooms as part of a focused drug development program."

This announcement follows Numinus' advocacy work that contributed to Health Canada's groundbreaking announcement of its intention to revise the Special Access Programme (SAP) to permit access to MDMA and psilocybin-assisted psychotherapy in the same way other investigational medications are accessed in Canada. In addition, earlier this week Numimius announced the exciting acquisition of Montreal -based Mindspace Psychology Services Inc (DBA Mindspace Wellbeing) bringing together the capabilities of two leading Canadian organizations to develop and scale delivery of evidence-based psychedelic-assisted psychotherapy.

Health Canada's Notice of Intent regarding the SAP will be open for public consultation and comments for the next 60 days, and Numinus strongly encourages the community to weigh in on the benefits of the revision. View the notice here: http://www.gazette.gc.ca/rp-pr/p1/2020/2020-12-12/html/notice-avis-eng.html#nb2.

To share comments and thoughts related to the SAP, please email hc.csd.regulatory.policy-politique.reglementaire.dsc.sc@canada.ca.

Aphria Inc. (TSX: APHA) (NASDAQ: APHA), a leading global cannabis company inspiring and empowering the worldwide community to live their best life, today announced the launch of Broken Coast Cannabis Inc.'s newest innovation and proprietary strain, Pipe Dream.

With its unique and distinctive characteristics, which include a bold bud structure, strong smell and look, and a spicy-gas profile with high THC (18-24%) content, 'Pipe Dream' was ultimately selected as the newest Broken Coast flower strain after 15-months of careful testing at its British Columbia-based cultivation facility.

"There aren't many cannabis plants that are genetically different to what's out there," said Kevin Anderson, Broken Coast's Head Grower. "To find a plant that scores so high in all regards of our testing is really one in several hundred - it's very rare. Pipe Dream is the one in several hundred and we think Canadians will really love the spicy and gassy profile, as it's truly different to anything else in our current strain offering but still the high-quality product consumers have come to expect from Broken Coast."

To unearth a cultivar worthy of the Broken Coast brand required the master grow team to plant, nurture and evaluate thousands of seedlings, seeking to identify and accentuate the traits that produce a truly exceptional smoke. Some felt a flower this special was nothing but a Pipe Dream. Now Canadians can decide for themselves.

Pipe Dream has a very dense and round bud structure thickly covered with bright trichomes. The lime green and purple flower also has a touch of fruitiness within its spicy and pungent profile. Pipe Dream is available in BC in 3.5g whole flower online and in retail and will be rolling out to the rest of the country (except for Quebec) over the next few months. In addition, 5g and 10g formats are also available to medical clients.

This is the second innovation recently launched by Broken Coast, following the recently announced expansion of its product portfolio and entry into the 2.0 market with the launch of 510 vapes.

Pure Harvest Corporate Group, Inc. (OTCQB: PHCG), a publicly-traded holding company focused on emerging and high-growth industries, announced the development of a cannabinoid compound which the Company believes has numerous applications as a versatile product ingredient. The working name for the cannabinoid compound is “Complex 612.”

“Complex 612 is a patent pending formulation created through extracting and compressing specific compounds within the hemp plant. Together with the addition of an antioxidant synergist to augment bioavailability and predictably of the experience in the ‘vehicle’ it is utilized within traditional, functional foods, confections, and beverages. Complex 612 also serves as a catalyst when paired with a variety of active compounds from plants including mushrooms, adaptogens, nootropics and others,” said Dr. James Rouse, NMD, Test Kitchen Chief Formulator. “The possibilities are limitless.”

“We believe Complex 612 and the wide variety of products and product enhancements that will come from it will be a game changer for the Company and this industry,” stated Matthew Gregarek, CEO, Pure Harvest Corporate Group. “We are already far down the road in our product development and planned roll-out and we are extremely excited to bring this product to market.

“Renowned cannabis attorney Donnie Emmi will officiate the product development and launch as CEO of our wholly owned subsidiary Test Kitchen and world-class marketing consultants Shipyard are handling everything from branding to our go-to-market strategy.

“I believe that I have truly assembled an All-Star team worthy of this tremendous innovation and am so immensely proud of what we’ve done and excited about what the very near future holds for Pure Harvest and its shareholders,” added Gregarek.

22nd Century Group, Inc. (NYSE: XXII), a leading plant-based, biotechnology company focused on tobacco harm reduction, very low nicotine content tobacco, and hemp/cannabis research, announced today that it was granted a new U.S. patent related to the control of cannabinoid and terpene production in plants. This new intellectual property exclusively provides 22nd Century with unique and powerful tools to alter the cannabinoid biosynthesis pathway in hemp/cannabis plants.

"We are delighted to receive this patent, which is the result of work carried out by our own scientists. This important, new technology will allow us to genetically modify hemp/cannabis plants to modulate their cannabinoid and terpene profiles in order to tailor these plants’ therapeutic qualities and enhance the consumer’s hemp/cannabis experience," said Juan Sanchez Tamburrino, Ph.D., vice president of research & development at 22nd Century Group. "Our patent application describes eight promoters, which are essentially molecular on/off switches, covering all of the major steps in the cannabinoid biosynthesis pathway. Typically, developing hemp/cannabis plants with new cannabinoid or terpene profiles could take 10 to 20 years using traditional breeding methods. Now, with the combined technologies and know-how of 22nd Century and KeyGene, we expect to shorten the development timeline to create new, differentiated, hemp/cannabis plant lines in just 4 to 5 years. Doing so will provide the Company and its potential licensees and customers with significant competitive advantage as hemp/cannabis continues to penetrate the life science, consumer product, and pharmaceutical markets.”

“At 22nd Century Group, we take a scientific and solutions-oriented approach to advancing ground-breaking, plant-based technology. We are excited to secure this patent, and we believe that it demonstrates our unique and leading role in plant science innovation within the $100 billion global hemp/cannabis market,” said James A. Mish, chief executive officer of 22nd Century Group.

The new patent, published as U.S. Patent No. 10,787,674 B2 and entitled "Trichome specific promoters for the manipulation of cannabinoids and other compounds in glandular trichomes," enables 22nd Century to develop and deliver new hemp/cannabis plants that are designed to produce cannabinoids more efficiently. The Company can potentially increase the yield of plants, stabilize the level of cannabinoids that are produced, and create custom cannabinoid profiles optimized for specific therapeutic uses. 22nd Century will also be able to potentially modulate the terpene levels within the plant – increasing them to deliver new strains of cannabis for the adult-use/recreational market and reducing them to remove the odor and taste for improved application in foods and beverages.

Cannabinoids, such as CBD, CBC, and CBG, are valuable compounds that hold great promise for the development of new medicines and other therapeutic applications. Cannabis sativa is the only plant species that produces significant amounts of these compounds including more than one hundred different cannabinoids in varying quantities. In nature, cannabis plants restrict production of these potentially toxic compounds to the trichomes which are tiny hair-like stems and globes that grow on the surface of the plant. To successfully manipulate cannabinoids, the Company’s new technology activates molecular promoters, “on/off switches,” specifically and only in the plant’s trichomes where the majority of cannabinoids are produced. These regulatory sequences dynamically enhance or restrict gene expression levels, controlling the expression of genetic information that leads to the production of cannabinoids.

Investors can trade these stocks and other ideas on our site using our list of top stock trading apps including Robinhood, Acorn, Stash and others.

Learn more about our cannabis podcasts at https://www.investorideas.com/Audio/Potcasts.asp

Or www.potcasts.ca

To hear more Investorideas.com podcasts visit: https://www.investorideas.com/Audio/.

Investorideas.com podcasts are also available on iTunes, Spotify, Google Play Music, Stitcher, Spreaker, YouTube via Spreaker, iHeartradio and Tunein.

Potcasts is now a certified word mark Trademark on the blockchain through Cognate, Inc. CM Certification-Registration Number: 10468217708

About Investorideas.com - News that Inspires Big Investing Ideas

More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

Investor Ideas does not condone the use of cannabis except where permissible by law. Our site does not possess, distribute, or sell cannabis products.

Learn more about sponsoring this podcast or be a guest and our other branded content opportunities at Investorideas.com

Download our Mobile App for iPhone and Android

Join our Investor Club https://www.investorideas.com/membership/

Contact Investorideas.com

800 665 0411

Get more Cannabis Stock Investor Ideas – news, articles, podcasts and stock directory

about Investorideas.com

About Investorideas.com - News that Inspires Big Investing Ideas